March 11, 2025 01:37 PM EDT

Gilead plans to skip from Phase 1 to Phase 3 with once-yearly HIV prevention drug

Lei Lei Wu

News Reporter

Gilead said two experimental once-a-year versions of its HIV prevention shot lenacapavir passed muster in an early-stage study with a small group of healthy participants …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Gilead plans to skip from Phase 1 to Phase 3 with once-yearly HIV prevention drug

Lei Lei Wu

News Reporter

Sign up to read this article for free.

Vice President, Biology & Translational Research

Gondolabio

Palo Alto, CA, USA

Updated: Zealand partners with Roche on its amylin analog in a deal worth up to $5.3B

Ono licenses rare blood disease drug from Ionis for $280M upfront

Legend to double Carvykti production as it targets blockbuster status

FDA’s medical review departments remain untouched (for now) by Musk’s cuts

Merck scores a win in Gardasil cases after judge says plaintiffs’ evidence ‘falls far short’

Obesity drug development—still room to grow

Gilead plans to skip from Phase 1 to Phase 3 with once-year­ly HIV pre­ven­tion drug

News Reporter

Sign up to read this article for free.

Gondolabio

Palo Alto, CA, USA

Gilead plans to skip from Phase 1 to Phase 3 with once-yearly HIV prevention drug